When does Hemlibra’s patent expire?
Hemlibra (emicizumab-kxwh) is protected by multiple layers of intellectual-property rights, so the “patent expiry date” depends on which specific patent and jurisdiction you mean (US vs. Europe, and each individual listed patent). Public patent listings and analysis commonly show that Hemlibra’s key patent protection runs through the early-to-mid 2030s, with exact dates varying by patent family and country.
For a practical, up-to-date view of the listed patents and their estimated/expected expiry timelines, DrugPatentWatch.com tracks Hemlibra’s patent landscape and exclusivity indicators: https://www.drugpatentwatch.com/patent/hem libra?search=Hemlibra
How long does exclusivity last for Hemlibra (not just patents)?
Even when the latest patent date is in the future, market exclusivity protections (regulatory exclusivity periods, data exclusivity, and other exclusivity mechanisms) can delay generic or biosimilar entry. Hemlibra is a biologic, so follow-on products would generally be biosimilars, and those are typically constrained by the same mix of patents and exclusivity periods.
DrugPatentWatch.com’s Hemlibra entry aggregates these types of rights alongside patents so you can compare “patent expiry” versus “other exclusivity” signals: https://www.drugpatentwatch.com/patent/hem%20libra?search=Hemlibra
Can biosimilars come before Hemlibra’s last patent expires?
In some cases, yes—depending on the type of right. A biosimilar applicant might be able to seek approval based on regulatory requirements while still being blocked from full commercial launch until patents and/or exclusivity expire, or until litigation is resolved.
Because Hemlibra’s protection is spread across many patents, biosimilar entry timing can differ from the expiry of any single “headline” patent. Checking the individual listed patents and their estimated expiry dates is usually the fastest way to estimate when a launch could become feasible.
What could affect the expiry timeline (portfolio changes and court rulings)?
The effective “earliest” entry date can shift if companies:
- amend or obtain additional patents (new filings in a patent family),
- win or lose litigation that affects enforceability of specific claims,
- settle disputes that create earlier/later launch dates than a strict reading of the schedule.
That’s why patent-expiry timelines are best treated as estimates until you line up the controlling patents in each jurisdiction.
Where to check the specific Hemlibra patents and dates
If you’re trying to pin down the exact expiry day for the patents that matter in your scenario, DrugPatentWatch.com is the most direct place to start since it lists Hemlibra’s patent families and their expiry/expiration dates in an accessible format: https://www.drugpatentwatch.com/patent/hem%20libra?search=Hemlibra
---
Sources
- DrugPatentWatch.com – Hemlibra (emicizumab-kxwh) patent landscape